Shopping Cart
Remove All
Your shopping cart is currently empty
CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with IC50 values of 123, 19.8, 26.8, and 74.3 nM for CK1a, CK1d, CK1e, and p38a, respectively, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $68 | - | In Stock | |
| 5 mg | $166 | - | In Stock | |
| 10 mg | $269 | - | In Stock | |
| 25 mg | $397 | - | In Stock | |
| 50 mg | $569 | - | In Stock |
| Description | CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with IC50 values of 123, 19.8, 26.8, and 74.3 nM for CK1a, CK1d, CK1e, and p38a, respectively, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy. |
| Targets&IC50 | CKIα:123 nM, CK1a:19.8 nM, CK1e:74.3 nM, CK1d:26.8 nM |
| In vitro | CK1-IN-2 (compound No. 4) is a potent inhibitor of casein kinase 1 (CK1), with IC₅₀ values of 123 nM (CK1α), 19.8 nM (CK1a), 26.8 nM (CK1d), and 74.3 nM (CK1e), indicating subtype selectivity[1]. CK1-IN-2 (0.02-10 μM, 72 h) promotes myotube formation in FSHD (facioscapulohumeral muscular dystrophy) cells, indicating its role in enhancing muscle cell fusion[1]. At 10 μM (72 h), CK1-IN-2 is also capable of reversing the inhibitory effect of Losmapimod on myotube formation[1]. |
| Molecular Weight | 309.29 |
| Formula | C17H12FN3O2 |
| Cas No. | 1383376-92-8 |
| Smiles | O=C1OCC2=NC=CC(C3=CN(N=C3C=4C=CC(F)=CC4)C)=C12 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (129.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.